Trials / Completed
CompletedNCT00567060
Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)
A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of 9600 and 4800 mg/Day Piracetam Taken for 12 Months by Subjects Suffering From Mild Cognitive Impairment (MCI)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 676 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 50 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to explore in a more documented way the relative potential and efficacy of piracetam 9600 and 4800 mg daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Piracetam |
Timeline
- Start date
- 2000-05-01
- Primary completion
- 2004-01-01
- Completion
- 2004-01-01
- First posted
- 2007-12-04
- Last updated
- 2013-12-16
Source: ClinicalTrials.gov record NCT00567060. Inclusion in this directory is not an endorsement.